Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference26 articles.
1. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS);Reiner;Eur Heart J,2011
2. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines;Grundy;Circulation,2004
3. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins;Lancet,2005
4. Canadian Cardiovascular Society position statement–recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease;McPherson;Can J Cardiol,2006
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report;Circulation,2002
Cited by 321 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial;The Lancet Diabetes & Endocrinology;2024-02
2. The use of statins and inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK 9) in patients with dyslipidemia;Glavvrač (Chief Medical Officer);2024-01-22
3. A bibliometric analysis of PCSK9 inhibitors from 2007 to 2022;Frontiers in Endocrinology;2023-11-29
4. PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis;Cureus;2023-10-06
5. Erupción liquenoide asociada al uso de alirocumab, presentación de un caso;Actas Dermo-Sifiliográficas;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3